Tumor Budding May Be a Promising Prognostic Indicator in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Study

Overview

Journal Ann Gastroenterol Surg

Date 2023 Jan 16

PMID 36643363

Authors

Hisashi Kosaka

Mitsuaki Ishida

Masaki Ueno

Koji Komeda

Daisuke Hokutou

Hiroya Iida

Fumitoshi Hirokawa

Kosuke Matsui

Mitsugu Sekimoto

Masaki Kaibori

Affiliations

Soon will be listed here.

Abstract

Purpose: This retrospective study evaluated our hypothesis that high tumor budding (≥10 buds) may help determine the appropriate T category for more accurate staging of intrahepatic cholangiocarcinoma (ICC).

Methods: We analyzed the clinical and histopathologic data of 235 consecutive patients with histologically confirmed ICC following hepatectomy at five university hospitals in the Kansai region of Japan between January 2009 and December 2020. ICC staging was based on the Liver Cancer Study Group of Japan (LCSGJ) staging system, 6th edition.

Results: Patients with ICC with high budding showed significantly shorter disease-specific survival (DSS) and disease-free survival (DFS) than patients with low/intermediate budding. Cox proportional hazards regression analysis showed a hazard ratio of 2.2-2.3 ( < 0.05) for high budding. Based on these results, we modified the T category of ICC in the LCSGJ staging system by adding severity of tumor budding as a fourth determinant. This proposed staging system for ICC has significantly improved the prognostic accuracy for both DSS and DFS (both: < 0.05).

Conclusions: High tumor budding is a new candidate for an additional determinant of the T category in staging ICC. An LCSGJ staging system containing an additional evaluation of tumor budding may lead to improved staging accuracy.

Citing Articles

Relationship of Desmoplastic Reaction and Tumour Budding in Primary and Lung Metastatic Lesions of Colorectal Cancer and Their Prognostic Significance.

Kobayashi T, Ishida M, Matsui H, Uehara H, I S, Yamada N Cancers (Basel). 2025; 17(4).

PMID: 40002175 PMC: 11852406. DOI: 10.3390/cancers17040583.

KRAS Mutation Status in Relation to Clinicopathological Characteristics of Romanian Colorectal Cancer Patients.

Avadanei E, Caruntu I, Nuca I, Balan R, Lozneanu L, Giusca S Curr Issues Mol Biol. 2025; 47(2).

PMID: 39996841 PMC: 11854687. DOI: 10.3390/cimb47020120.

Prognostic scoring system based on indicators reflecting the tumor glandular differentiation and microenvironment for patients with colorectal cancer.

Kobayashi T, Ishida M, Miki H, Yamamoto N, Harino T, Yagyu T Sci Rep. 2024; 14(1):14188.

PMID: 38902294 PMC: 11189912. DOI: 10.1038/s41598-024-65015-2.

Association of tumor budding with clinicopathological features and prognostic value in stage III-IV colorectal cancer.

Luo Y, Yan Z, Liu J, Li X, Yang M, Fan J World J Gastroenterol. 2024; 30(2):158-169.

PMID: 38312121 PMC: 10835523. DOI: 10.3748/wjg.v30.i2.158.

Tumor budding as a potential prognostic marker in determining the behavior of primary liver cancers.

Unal B, Celik M, Gedik E, Bassorgun C, Elpek G World J Hepatol. 2023; 15(6):775-785.

PMID: 37397937 PMC: 10308291. DOI: 10.4254/wjh.v15.i6.775.

References

Si A, Li J, Yang Z, Xia Y, Yang T, Lei Z . Impact of Anatomical Versus Non-anatomical Liver Resection on Short- and Long-Term Outcomes for Patients with Intrahepatic Cholangiocarcinoma. Ann Surg Oncol. 2019; 26(6):1841-1850. DOI: 10.1245/s10434-019-07260-8. View

Jesinghaus M, Boxberg M, Konukiewitz B, Slotta-Huspenina J, Schlitter A, Steiger K . A Novel Grading System Based on Tumor Budding and Cell Nest Size Is a Strong Predictor of Patient Outcome in Esophageal Squamous Cell Carcinoma. Am J Surg Pathol. 2017; 41(8):1112-1120. DOI: 10.1097/PAS.0000000000000865. View

Kosaka H, Kaibori M, Matsui K, Ishizaki M, Matsushima H, Sekimoto M . Investigation of a Tumor Location-Specific Therapeutic Strategy for Intrahepatic Cholangiocarcinoma. Asian Pac J Cancer Prev. 2021; 22(5):1485-1493. PMC: 8408380. DOI: 10.31557/APJCP.2021.22.5.1485. View

Siebenhuner A, Seifert H, Bachmann H, Seifert B, Winder T, Feilchenfeldt J . Adjuvant treatment of resectable biliary tract cancer with cisplatin plus gemcitabine: A prospective single center phase II study. BMC Cancer. 2018; 18(1):72. PMC: 5765636. DOI: 10.1186/s12885-017-3967-0. View

Ohike N, Coban I, Kim G, Basturk O, Tajiri T, Krasinskas A . Tumor budding as a strong prognostic indicator in invasive ampullary adenocarcinomas. Am J Surg Pathol. 2010; 34(10):1417-24. PMC: 3163902. DOI: 10.1097/PAS.0b013e3181f0b05a. View

Kang S, Hwang S, Lee Y, Kim K, Ahn C, Moon D . Prognostic comparison of the 7th and 8th editions of the American Joint Committee on Cancer staging system for intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2018; 25(4):240-248. DOI: 10.1002/jhbp.543. View

Endo I, Gonen M, Yopp A, Dalal K, Zhou Q, Klimstra D . Intrahepatic cholangiocarcinoma: rising frequency, improved survival, and determinants of outcome after resection. Ann Surg. 2008; 248(1):84-96. DOI: 10.1097/SLA.0b013e318176c4d3. View

Yoh T, Cauchy F, Le Roy B, Seo S, Taura K, Hobeika C . Prognostic value of lymphadenectomy for long-term outcomes in node-negative intrahepatic cholangiocarcinoma: A multicenter study. Surgery. 2019; 166(6):975-982. DOI: 10.1016/j.surg.2019.06.025. View

Edeline J, Benabdelghani M, Bertaut A, Watelet J, Hammel P, Joly J . Gemcitabine and Oxaliplatin Chemotherapy or Surveillance in Resected Biliary Tract Cancer (PRODIGE 12-ACCORD 18-UNICANCER GI): A Randomized Phase III Study. J Clin Oncol. 2019; 37(8):658-667. DOI: 10.1200/JCO.18.00050. View

10.

Cheng Z, Lei Z, Si A, Yang P, Luo T, Guo G . Modifications of the AJCC 8th edition staging system for intrahepatic cholangiocarcinoma and proposal for a new staging system by incorporating serum tumor markers. HPB (Oxford). 2019; 21(12):1656-1666. DOI: 10.1016/j.hpb.2019.05.010. View

11.

Liao X, Zhang D . The 8th Edition American Joint Committee on Cancer Staging for Hepato-pancreato-biliary Cancer: A Review and Update. Arch Pathol Lab Med. 2020; 145(5):543-553. DOI: 10.5858/arpa.2020-0032-RA. View

12.

Buettner S, van Vugt J, IJzermans J, Groot Koerkamp B . Intrahepatic cholangiocarcinoma: current perspectives. Onco Targets Ther. 2017; 10:1131-1142. PMC: 5328612. DOI: 10.2147/OTT.S93629. View

13.

Shaib Y, Davila J, McGlynn K, El-Serag H . Rising incidence of intrahepatic cholangiocarcinoma in the United States: a true increase?. J Hepatol. 2004; 40(3):472-7. DOI: 10.1016/j.jhep.2003.11.030. View

14.

Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D . Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. View

15.

Okubo S, Mitsunaga S, Kato Y, Kojima M, Sugimoto M, Gotohda N . The prognostic impact of differentiation at the invasive front of biliary tract cancer. J Surg Oncol. 2018; 117(6):1278-1287. DOI: 10.1002/jso.24946. View

16.

Kosaka H, Ishida M, Ueno M, Komeda K, Hokutou D, Iida H . Tumor budding may be a promising prognostic indicator in intrahepatic cholangiocarcinoma: A multicenter retrospective study. Ann Gastroenterol Surg. 2023; 7(1):138-146. PMC: 9831894. DOI: 10.1002/ags3.12605. View

17.

Ito T, Kuriyama N, Kozuka Y, Komatsubara H, Ichikawa K, Noguchi D . High tumor budding is a strong predictor of poor prognosis in the resected perihilar cholangiocarcinoma patients regardless of neoadjuvant therapy, showing survival similar to those without resection. BMC Cancer. 2020; 20(1):209. PMC: 7069056. DOI: 10.1186/s12885-020-6695-9. View

18.

Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H . Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Mod Pathol. 2017; 30(9):1299-1311. DOI: 10.1038/modpathol.2017.46. View

19.

Tanaka M, Yamauchi N, Ushiku T, Shibahara J, Hayashi A, Misumi K . Tumor Budding in Intrahepatic Cholangiocarcinoma: A Predictor of Postsurgery Outcomes. Am J Surg Pathol. 2019; 43(9):1180-1190. DOI: 10.1097/PAS.0000000000001332. View

20.

Kim Y, Moris D, Zhang X, Bagante F, Spolverato G, Schmidt C . Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis. J Surg Oncol. 2017; 116(6):643-650. DOI: 10.1002/jso.24720. View